Which medication is associated with extended survival time in patients with amyotrophic lateral sclerosis (ALS)?

Riluzole is recognized as the medication associated with extended survival time in patients with amyotrophic lateral sclerosis (ALS). This drug works by inhibiting the release of glutamate, which is a neurotransmitter that, in excessive amounts, can be toxic to motor neurons. By reducing glutamate levels, Riluzole helps to slow down the progression of the disease, resulting in prolonged survival and improved quality of life for patients.

Its effectiveness has been supported by clinical trials, which have shown that Riluzole can extend survival by several months compared to placebo treatment. This makes it a crucial component of ALS management and reflects its significant impact on the disease's course.

Other medications listed, such as Edaravone, have been associated with potential benefits in terms of function and quality of life but do not show the same level of evidence for extending survival time as Riluzole. Dexamethasone and amino acids do not have established roles in the treatment of ALS in terms of survival benefits.